Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 225-228

  Tas, Faruk ^a   Yasasever, Vildan ^a   Duranyildiz, Derya ^a   Camlica, Hakan ^a   Ustuner, Zeki ^a   Aydiner, Adnan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Melanoma; Melanoma inhibitory protein (MIA); S100

Indexed keywords

MELANOMA INHIBITORY PROTEIN; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MALE; MELANOMA; METASTASIS; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; S100 PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2942593695     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000054895.39558.DB     Document Type: Article

References (20)

1. Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 2000;143:256-68.
2. Apfel R, Lottspeich F, Hoppe J, et al. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 1992;2:327-36.
3. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. TIBS 1996;21:134-40.
4. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995;31A: 924-8.
5. Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibiting activity, a novel serum tumor marker for progression of malignant melanoma. Cancer Res 1997;57:3149-53.
6. Miliotes G, Lyman GH, Cruse CW, et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996;3:558-63.
7. Bonfrer JMG, de Feij-de Graaf HM, Nyberg L. The LIA-mat Sangtec 100 assay: a sensitive test to measure the concentration of S-100 protein in serum. In: XXIV Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), San Diego, USA, November 17-22, ISOBM, San Diego, CA, USA, (Abstract), 1996.
8. Hauschild A, Michaelsen J, Brenner W, et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999;9:155-61.
9. Schultz ES, Diepgen TL, von den Driesch P. Clinical and prognostic relevance of serum S-100β protein in malignant melanoma. Br J Dermatol 1998;138:426-30.
10. Buer J, Probst M, Franzke A, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997;75:1373-6.
11. von Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S-1000 protein in malignant melanoma. Melanoma Res 1996;6:133-7.
12. Bonfrer JMG, Korse CM, Israels SP. Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res 1997;17:2975-8.
13. Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999;56:338-44.
14. Martenson ED, Hansson LO, Nilsson B. S-100B and melanoma inhibiting activity (MIA): new prognostic serum markers in patients with malignant melanoma. In: Third International Conference on the Adjuvant Therapy of Malignant Melanoma, London, March 19-20. Royal College of Physicians. London, UK, (Abstract), 1999.
15. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-71.
16. Mühbauer M, Langenbach N, Stolz W, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999;5:1099-105.
17. Schmitz C, Brenner W, Henze E, et al. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000;20:5059-64.
18. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma inhibiting activity, and lactate dehydrogenase discriminate progressive American Joint Committee on cancer stage IV melanoma. J Clin Oncol 1999;17:1891-6.
19. Juergensen A, Holzaphel U, Hein R, et al. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 2001;22:54-8.
20. Djukanovic D, Hofmann U, Sucker A, et al. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000;20:2203-7.